These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38052529)

  • 1. Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer.
    Lima EABF; Song PN; Reeves K; Larimer B; Sorace AG; Yankeelov TE
    Math Biosci Eng; 2023 Sep; 20(10):17625-17645. PubMed ID: 38052529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    McNeal KC; Reeves KM; Song PN; Lapi SE; Sorace AG; Larimer BM
    Nucl Med Biol; 2024; 134-135():108918. PubMed ID: 38772123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
    Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY
    Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
    [No Abstract]   [Full Text] [Related]  

  • 6. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Grkovski M; Fanchon L; Pillarsetty NVK; Russell J; Humm JL
    EJNMMI Res; 2018 Jun; 8(1):53. PubMed ID: 29916085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
    Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
    Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
    Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.
    Stokes AM; Hart CP; Quarles CC
    Tomography; 2016 Sep; 2(3):229-237. PubMed ID: 27752544
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Reeves KM; Song PN; Angermeier A; Della Manna D; Li Y; Wang J; Yang ES; Sorace AG; Larimer BM
    Clin Cancer Res; 2022 Jan; 28(2):327-337. PubMed ID: 34615724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
    Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
    Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
    Sun JD; Ahluwalia D; Liu Q; Li W; Wang Y; Meng F; Bhupathi D; Matteucci MD; Hart CP
    Am J Cancer Res; 2015; 5(7):2139-55. PubMed ID: 26328245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [
    Nakajima K; Homma M; Suzuki M; Yokouchi Y; Matsuda T; Takakura H; Hirata K; Kuge Y; Ogawa M
    Nucl Med Biol; 2022; 108-109():85-92. PubMed ID: 35367730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
    Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
    Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.
    Kumar S; Sun JD; Zhang L; Mokhtari RB; Wu B; Meng F; Liu Q; Bhupathi D; Wang Y; Yeger H; Hart C; Baruchel S
    Transl Oncol; 2018 Aug; 11(4):911-919. PubMed ID: 29803017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia imaging with
    Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P
    Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair.
    Otowa Y; Kishimoto S; Saida Y; Yamashita K; Yamamoto K; Chandramouli GVR; Devasahayam N; Mitchell JB; Krishna MC; Brender JR
    Antioxid Redox Signal; 2023 Sep; 39(7-9):432-444. PubMed ID: 37051681
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.